RNXT
RenovoRx, Inc.Company with tickers: RNXT
Market Cap
$42.52M
Shares Outstanding
45,052,706
CIK
1574094
CUSIP
75989R107
Website
Visit website
Investor Relations
Investor relations
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $563,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | $84,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Gross Profit | $479,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Expenses | $3,948,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $1,228,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-3,469,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-3,521,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.09 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.09 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2024-12-31 | 2025-12-31 |
|---|---|---|
| All Other Segments | $43,000 | $1,123,000 |